ArticleCancer chemotherapy and pharmacology2026

Timing of dose reduction matters: interpreting survival outcomes with CDK4/6 inhibitors in advanced breast cancer.

Kadri AltundagPubMed ↗Publisher ↗

No numbers read from the abstract.